Browse > Article
http://dx.doi.org/10.4196/kjpp.2017.21.6.687

Biphasic augmentation of alpha-adrenergic contraction by plumbagin in rat systemic arteries  

Kim, Hae Jin (Department of Physiology, Seoul National University College of Medicine)
Yoo, Hae Young (Chung-Ang University Red Cross College of Nursing)
Zhang, Yin Hua (Department of Physiology, Seoul National University College of Medicine)
Kim, Woo Kyung (Department of Internal Medicine, Graduate School of Medicine, Dongguk University)
Kim, Sung Joon (Department of Physiology, Seoul National University College of Medicine)
Publication Information
The Korean Journal of Physiology and Pharmacology / v.21, no.6, 2017 , pp. 687-694 More about this Journal
Abstract
Plumbagin, a hydroxy 1,4-naphthoquinone compound from plant metabolites, exhibits anticancer, antibacterial, and antifungal activities via modulating various signaling molecules. However, its effects on vascular functions are rarely studied except in pulmonary and coronary arteries where NADPH oxidase (NOX) inhibition was suggested as a mechanism. Here we investigate the effects of plumbagin on the contractility of skeletal artery (deep femoral artery, DFA), mesenteric artery (MA) and renal artery (RA) in rats. Although plumbagin alone had no effect on the isometric tone of DFA, $1{\mu}M$ phenylephrine (PhE)-induced partial contraction was largely augmented by plumbagin (${\Delta}T_{Plum}$, 125% of 80 mM KCl-induced contraction at $1{\mu}M$). With relatively higher concentrations (>$5{\mu}M$), plumbagin induced a transient contraction followed by tonic relaxation of DFA. Similar biphasic augmentation of the PhE-induced contraction was observed in MA and RA. VAS2870 and GKT137831, specific NOX4 inhibitors, neither mimicked nor inhibited ${\Delta}T_{Plum}$ in DFA. Also, pretreatment with tiron or catalase did not affect ${\Delta}T_{Plum}$ of DFA. Under the inhibition of PhE-contraction with L-type $Ca^{2+}$ channel blocker (nifedipine, $1{\mu}M$), plumbagin still induced tonic contraction, suggesting $Ca^{2+}$-sensitization mechanism of smooth muscle. Although ${\Delta}T_{Plum}$ was consistently observed under pretreatment with Rho A-kinase inhibitor (Y27632, $1{\mu}M$), a PKC inhibitor (GF 109203X, $10{\mu}M$) largely suppressed ${\Delta}T_{Plum}$. Taken together, it is suggested that plumbagin facilitates the PKC activation in the presence of vasoactive agonists in skeletal arteries. The biphasic contractile effects on the systemic arteries should be considered in the pharmacological studies of plumbagin and 1,4-naphthoquinones.
Keywords
Artery; Contraction; Plumbagin; Protein kinase C; Smooth muscle;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Padhye S, Dandawate P, Yusufi M, Ahmad A, Sarkar FH. Perspectives on medicinal properties of plumbagin and its analogs. Med Res Rev. 2012;32:1131-1158.   DOI
2 Courboulin A, Barrier M, Perreault T, Bonnet P, Tremblay VL, Paulin R, Tremblay E, Lambert C, Jacob MH, Bonnet SN, Provencher S, Bonnet S. Plumbagin reverses proliferation and resistance to apoptosis in experimental PAH. Eur Respir J. 2012;40:618-629.   DOI
3 Ding Y, Chen ZJ, Liu S, Che D, Vetter M, Chang CH. Inhibition of Nox-4 activity by plumbagin, a plant-derived bioactive naphthoquinone. J Pharm Pharmacol. 2005;57:111-116.   DOI
4 Ahmad M, Kelly MR, Zhao X, Kandhi S, Wolin MS. Roles for Nox4 in the contractile response of bovine pulmonary arteries to hypoxia. Am J Physiol Heart Circ Physiol . 2010;298:H1879-1888.   DOI
5 Smith RM, Kruzliak P, Adamcikova Z, Zulli A. Role of Nox inhibitors plumbagin, ML090 and gp91ds-tat peptide on homocysteine thiolactone induced blood vessel dysfunction. Clin Exp Pharmacol Physiol. 2015;42:860-864.   DOI
6 Han JA, Seo EY, Kim HJ, Park SJ, Yoo HY, Kim JY, Shin DM, Kim JK, Zhang YH, Kim SJ. Hypoxia-augmented constriction of deep femoral artery mediated by inhibition of eNOS in smooth muscle. Am J Physiol Cell Physiol . 2013;304:C78-88.   DOI
7 Altenhofer S, Radermacher KA, Kleikers PW, Wingler K, Schmidt HH. Evolution of NADPH oxidase inhibitors: selectivity and mechanisms for target engagement. Antioxid Redox Signal. 2015;23:406-427.   DOI
8 Kim JA, Neupane GP, Lee ES, Jeong BS, Park BC, Thapa P. NADPH oxidase inhibitors: a patent review. Expert Opin Ther Pat. 2011;21:1147-1158.   DOI
9 Somlyo AP, Somlyo AV. $Ca^{2+}$ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev. 2003;83:1325-1358.   DOI
10 Hafeez BB, Zhong W, Mustafa A, Fischer JW, Witkowsky O, Verma AK. Plumbagin inhibits prostate cancer development in TRAMP mice via targeting $PKC\varepsilon$, Stat3 and neuroendocrine markers. Carcinogenesis. 2012;33:2586-2592.   DOI
11 Hafeez BB, Zhong W, Fischer JW, Mustafa A, Shi X, Meske L, Hong H, Cai W, Havighurst T, Kim K, Verma AK. Plumbagin, a medicinal plant (Plumbago zeylanica)-derived 1,4-naphthoquinone, inhibits growth and metastasis of human prostate cancer PC-3M-luciferase cells in an orthotopic xenograft mouse model. Mol Oncol. 2013;7:428-439.   DOI
12 Hafeez BB, Jamal MS, Fischer JW, Mustafa A, Verma AK. Plumbagin, a plant derived natural agent inhibits the growth of pancreatic cancer cells in in vitro and in vivo via targeting EGFR, Stat3 and $NF-{\kappa}B$ signaling pathways. Int J Cancer. 2012;131:2175-2186.   DOI
13 Way KJ, Chou E, King GL. Identification of PKC-isoform-specific biological actions using pharmacological approaches. Trends Pharmacol Sci. 2000;21:181-187.   DOI
14 Ringvold HC, Khalil RA. Protein kinase C as regulator of vascular smooth muscle function and potential target in vascular disorders. Adv Pharmacol . 2017;78:203-301.
15 Joo HK, Lee YR, Choi S, Park MS, Kang G, Kim CS, Jeon BH. Protein kinase C beta II upregulates intercellular adhesion molecule-1 via mitochondrial activation in cultured endothelial cells. Korean J Physiol Pharmacol. 2017;21:377-384.   DOI
16 Floreani M, Forlin A, Pandolfo L, Petrone M, Bellin S. Mechanisms of plumbagin action on guinea pig isolated atria. J Pharmacol Exp Ther. 1996;278:763-770.